Allopurinol Does Not Reduce CKD Progression

Restricted access

Urate-lowering therapy does not reduce the risk of progression in patients with chronic kidney disease (CKD), reports The New England Journal of Medicine.

The “Controlled Trial of Slowing of Kidney Disease Progression from the Inhibition of Xanthine Oxidase” (CKD-FIX) enrolled adults with stage 3 or 4 CKD (urinary albumin:creatinine ratio of 265 or higher or estimated glomerular filtration rate [eGFR] at least 3.0 mL/min/1.73 m2) and no history of gout. Patients were assigned to allopurinol, 100 to 300 mg/d, or placebo. The main outcome of interest was change in eGFR from baseline to 104 weeks.

Planned

Save